plerixafor has been researched along with Local Neoplasm Recurrence in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cassano, A; Chiusolo, P; Corbingi, A; Di Salvatore, M; Massini, G; Metafuni, E; Piccirillo, N; Putzulu, R; Rossi, E; Schinzari, G; Sica, S; Zini, G | 1 |
| Auner, HW; Basak, GW; Celanovic, M; Chabannon, C; Garderet, L; Hayden, P; Iacobelli, S; Knol, C; Kobbe, G; Krejci, M; Kröger, N; Lenhoff, S; Liu, Q; Masszi, T; Morris, C; Nahi, H; Pohlreich, D; Russell, N; Schaap, N; van Biezen, A | 1 |
| Bosman, P; Boumendil, A; Celanovic, M; Chabannon, C; Dabrowska-Iwanicka, A; Dreger, P; Esquirol, A; Janikova, A; Jantunen, E; Liu, Q; Masszi, T; Montoto, S; Pohlreich, D; Russell, N; Sakellari, I; Scheid, C; Sureda, A; Thieblemont, C; Touzeau, C; van der Werf, S; Wahlin, BE | 1 |
| Brown, JM | 1 |
| Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T | 1 |
| Athanasopoulos, A; Grivas, A; Karakosta, M; Kosma, A; Kosmas, C; Kranidioti, E; Lianos, E; Miltiadous, C | 1 |
| Athanasopoulos, A; Daladimos, T; Dimitriadis, G; Gekas, C; Kosmas, C; Lydakis, D; Magiorkinis, E; Miltiadous, C; Mylonakis, N; Zilakos, M; Ziras, N | 1 |
| Boucard, C; Chinot, O; Delfino, C; Denicolai, E; Figarella-Branger, D; Graillon, T; Metellus, P; Nanni, I; Ouafik, L; Padovani, L; Tabouret, E; Tchoghandjian, A | 1 |
| Burness, ML; Cheng, Q; Cheng, R; Comatas, K; Kim Lyerly, H; Lee, CH; Magnani, J; McCall, CM; Olivere, L; Price, TT; Sipkins, DA; Sivan, A; Warner, MJ | 1 |
| Cobb, WS; Greenfield, JP; Lyden, D | 1 |
| Brown, JM; Harsh, GR; Hoffman, RM; Kioi, M; Schultz, G; Vogel, H | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
1 review(s) available for plerixafor and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Radiation Damage to Tumor Vasculature Initiates a Program That Promotes Tumor Recurrences.
Topics: Benzylamines; Blood Vessels; Bone Marrow Cells; Cell Polarity; Chemokine CXCL12; Cyclams; Endothelial Cells; Humans; Hypoxia-Inducible Factor 1; Neoplasm Recurrence, Local; Neoplasms; Radiotherapy Dosage; Reactive Oxygen Species; Receptors, CXCR4; Tumor Hypoxia; Tumor-Associated Macrophages | 2020 |
2 trial(s) available for plerixafor and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult | 2017 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Receptors, CXCR4; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2012 |
9 other study(ies) available for plerixafor and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Successful "on-demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors.
Topics: Adolescent; Adult; Benzylamines; Blood Component Removal; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Peripheral Blood Stem Cell Transplantation; Peripheral Blood Stem Cells; Retrospective Studies; Transplantation, Autologous; Young Adult | 2022 |
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Registries | 2020 |
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.
Topics: Benzylamines; Bone Marrow; Cyclams; Europe; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Neoplasm Recurrence, Local; Registries | 2020 |
Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation;
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Combined Modality Therapy; Cyclams; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prognosis; Transplantation, Autologous; Young Adult | 2019 |
Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumo
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cisplatin; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Transplantation, Autologous; Young Adult | 2014 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine CXCL12; Chemoradiotherapy; Child; Child, Preschool; Cyclams; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Gene Expression Profiling; Glioblastoma; Heterocyclic Compounds; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Retrospective Studies; Signal Transduction; Temozolomide; Time Factors; Tissue Culture Techniques; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2015 |
Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone.
Topics: Animals; Benzylamines; Bone Marrow; Breast Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Cyclams; E-Selectin; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Immunohistochemistry; MCF-7 Cells; Mice; Mice, SCID; Microscopy, Confocal; Neoplasm Micrometastasis; Neoplasm Recurrence, Local; Protein Binding; Receptors, CXCR4; Tumor Cells, Cultured | 2016 |
Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas.
Topics: Animals; Anti-HIV Agents; Antibodies, Neutralizing; Antineoplastic Agents; Benzylamines; Bone Marrow Cells; Brain Neoplasms; CD11b Antigen; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Glioblastoma; Heterocyclic Compounds; Humans; Hypoxia-Inducible Factor 1; Mice; Mice, Nude; Monocytes; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, CXCR4; Transplantation, Heterologous; Whole-Body Irradiation | 2010 |
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.
Topics: Animals; Anti-HIV Agents; Antibodies, Neutralizing; Antineoplastic Agents; Benzylamines; Bone Marrow Cells; Brain Neoplasms; CD11b Antigen; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Glioblastoma; Heterocyclic Compounds; Humans; Hypoxia-Inducible Factor 1; Mice; Mice, Nude; Monocytes; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, CXCR4; Transplantation, Heterologous; Whole-Body Irradiation | 2010 |